LFA-1–deficient Mice Show Normal CTL Responses to Virus but Fail to Reject Immunogenic Tumor

By Rudolf Schmits,* Thomas M. Kündig,† Dianne M. Baker,§ Grace Shumaker,§ John J.L. Simard,*, Gordon Duncan,* Andrew Wakeham,* Arda Shahinian,* Annette van der Heiden,* Martin F. Bachmann,‡ Pamela S. Ohashi,‡ Tak W. Mak,* and Dennis D. Hickstein~

From the *Amgen Institute, Ontario Cancer Institute, Departments of Immunology and Medical Biophysics, and †Ontario Cancer Institute, Departments of Medical Biophysics and Immunology, University of Toronto, Toronto, Ontario M5G 2M9 Canada; and ~University of Washington School of Medicine and the Seattle Veterans Affairs Medical Center, Seattle, Washington 98108

Summary

The leukocyte integrin LFA-1 (CD11a/CD18) plays an important role in lymphocyte recirculation and homotypic interactions. Leukocytes from mice lacking CD11a displayed defects in in vitro homotypic aggregation, in proliferation in mixed lymphocyte reactions, and in response to mitogen. Mutant mice mounted normal cytotoxic T cell (CTL) responses against systemic LCMV and VSV infections and showed normal ex vivo CTL function. However, LFA-1–deficient mice did not reject immunogenic tumors grafted into footpads and did not demonstrate priming response against tumor-specific antigen. Thus CD11a deficiency causes a selective defect in induction of peripheral immune responses whereas responses to systemic infection are normal.

The CD11a/CD18 (LFA-1) complex, a cell adhesion molecule essential for cell-mediated cytotoxicity by T-lymphocytes (CTL) and natural killer (NK) cells, plays an important role in host defense (1, 2). The natural ligands for LFA-1 are ICAM-1, ICAM-2, and ICAM-3, which have been shown to facilitate interactions between T lymphocytes and endothelial tissues, target cells (3, 4), and antigen-presenting cells (APC) (5, 6). LFA-1 belongs to the β2-integrin family of adhesion molecules, whose members include MAC-1 (CD11b/CD18), p150,95 (CD11c/CD18), and a putative heterodimer recently described (7). The CD11b/CD18 heterodimer has been found to be important for non-specific adhesion of granulocytes and monocytes to endothelial cells, and CD11c/CD18 is reportedly a phagocyte receptor involved in activating cells after binding to bacterial LPS in infected tissues (8). LFA-1 is thought to be more involved in lymphocyte function (9) and is expressed on lymphocytes, monocytes, granulocytes, and bone marrow cells. A hereditary mutation in the β-chain (CD18) of the β2-integrin family results in a reduction or lack of a functional CD11a/CD18 (LFA-1), CD11b/CD18, and CD11c/CD18 heterodimers. Children affected by this lymphocyte adhesion deficiency (LAD) suffer from extreme susceptibility to bacterial and fungal infections (10–13).

Whereas a genetic defect in the CD18 gene results in the obliteration of all three β2 integrins, CD11a–deficient mice were expected to lack only the LFA-1 family member. Lymphocytes have been shown to require the LFA-1 heterodimer for normal inflammatory responses in vivo (3, 14). Early studies suggested that LFA-1 probably was crucial to early phase induction of immune responses but was not as important for lymphocyte proliferation (1, 15). Other results have implicated LFA-1 in recirculation and effector function of primed T lymphocytes. Simultaneous injection of anti–LFA-1 mAb with 2,4 dinitro-fluorobenzene (DNFB) rechallenge blocked DTH responses in DNFB-primed mice, which accompanied a significant reduction in the number of lymphocytes in lymph nodes draining treated skin (16). In addition, adoptive transfer of LCMV primed lymphocytes treated with anti–LFA-1 mAb blocked the development of DTH responses in naive recipient animals (17).

Early studies with T-cell lines indicated a possible functional role for LFA-1 in CTL killing of target cells (1, 18, 19). More recent reports have indicated that tumor-specific CTL against lymphoma cells require LFA-1 expression for normal killing responses (20), and that virus-induced tumor progression is enhanced in anti–LFA-1 treated mice, report-

1 Abbreviations used in this paper: DNFB, 2,4 dinitro-fluorobenzene; DTH, delayed-type hypersensitivity; ES, embryonic stem cells; LCMV, lymphocytic choriomeningitis virus; VSV, vesicular stomatitis virus.
We observed reduced proliferative responses of enriched T cells against ICAMs 1, 2, or 3 showed that dendritic cell and rolling at HEV (4). Lymphocytes expressing high levels of MEL-14 are also less susceptible to the effects of anti-LFA-1 antibody blocking effects on lymphocyte adhesion to HEV (22). This data on the role of LFA-1 in T cell recirculation raises questions as to the role of the molecule during normal homing responses in vivo.

Splenocytes deficient for ICAM-1 are almost totally defective as stimulators in an MLR (6). Antibody-blocking studies against ICAMs 1, 2, or 3 showed that dendritic cell APC function for T cells was abrogated by mAbs against ICAM-1 or 2 but not by mAb directed at ICAM-3 (5). Both induction and expansion of lymphocytes has been shown to require LFA-1. Anti-LFA-1 mAb block T cell induction phase to alloantigen but have no effect on proliferation during bulk expansion of allospecific T cells (23). These studies and others have revealed that the requirement of LFA-1 by T cells for proliferative responses to antigen can vary depending on the type of APC (24). Clarification is needed on the role of LFA-1 in the induction antigen-specific CTL.

We have disrupted the murine CD11a gene in embryonic stem cells (ES) cells and generated a mouse strain possessing targeted disruption of both alleles of the CD11a gene. We observed reduced proliferative responses of enriched T cells in in vitro MLR, and after mitogenic stimulation. Unexpectedly, CD11a homozygous mutant mice mounted normal T cell responses to lymphocyte choriomeningitis virus (LCMV) and vesicular stomatitis virus (VSV) infections and exhibited normal ex vivo CTL function. However, mutant mice showed defective peripheral priming against tumor cells expressing a tumor-specific antigen and in addition were unable to clear tumors injected into footpads.

**Materials and Methods**

**Preparation of Targeting Construct.** To prepare a gene targeting construct, a murine 129 genomic DNA library (Stratagene Inc., La Jolla, CA) was screened using oligonucleotides corresponding to the 5' end of the murine CD11a cDNA. A single lambda clone containing exons 1 to 6 was isolated. A construct for homologous recombination was prepared by ligation of a KpnI/Sall fragment (containing the pMC1neo polyA neomycin resistance cassette) with a 5-kgb 5' Xbal/KpnI fragment and a 0.6-kgb 3' Sall/Xbal fragment corresponding to the murine CD11a gene. The long arm of this construct contains exon 1 and part of intron 1, and the short arm contains the 3' portion of exon 6 and part of intron 6. The targeting construct replaces exons 2, 3, 4, 5, and part of exon 6 with the neomycin resistance cassette. The first six exons correspond to the signal peptide and the amino-terminal extracellular region of the CD11a gene. A 500-bp HindIII/BamHI restriction fragment immediately upstream of the region included in the mCD11a targeting construct was used as a probe in Southern blot analysis for targeted events.

**Generation of ES Cell Line and Mice.** The ES cell line E14 K was electroporated with the CD11a construct, which was linearized at the unique NotI site in the Bluescript polylinker at the 3' end. Individual colonies were picked after 10 d of selection in 500 μg/ml of G418 and analyzed by PCR using a primer contained within the neo cassette (5' AAC GCA CGG GTG TTG CGT TTG 3') paired with an outside primer (5' ACC AGT CTC TGC TTC TTC TGC AC 3') located in the murine CD11a gene 3' to the targeting construct. Positive clones identified by PCR were confirmed using Southern blotting and hybridizing with a flanking probe.

Targeted ES cell clones were injected into day 3.5 C57 BL/6J blastocysts and transferred into the uteri of CD1 pseudo-pregnant foster mothers, as previously described (25-27). Chimeric male and female offsprings were bred to C57 BL/6j, and germ-line transmission of the mutation was documented by PCR and by Southern blotting of tail DNA digested with EcoRI and hybridized with the 5' flanking probe. Mice demonstrating germ line transmission of the targeted allele were then bred to obtain homozygous gene targeted offspring and further backcrosses into C57 BL/6j.

**Analysis of Circulating Leukocyte Counts in the Gene-targeted Mice.** Peripheral blood of anesthetized mice was collected from the retroauricular plexus in EDTA-capped tubes or by cardiac puncture at the time of death. Whole blood was diluted 1:3 in Hanks BBS and total white blood cell counts determined on a hemocytometer. The absolute numbers of each leukocyte population were calculated by multiplying total white blood cell counts by differentials. Blood smears were prepared and stained with Leukostat (Sigma Chem. Co., St. Louis, MO) to count differentials.

**Flow Cytometry of Gene-targeted Mice.** Cell suspensions from thymus, spleen, lymph nodes, and bone marrow of 6- to 12-wk-old mice were prepared free from red blood cells. For two- and three-color flow cytometry, 5 × 10⁶ cells in 100 μl were stained with antibodies directly conjugated with FITC or PE: anti-CD11a (clone M17/4; PharMingen, San Diego, CA), anti-CD4 (clone YTS 191.12; Cedarlane Labs. Ltd., Hornby, ON), anti-CD8 (clone YTS 169.4; Cedarlane Labs.), anti-CD18 (clone C71/16), anti-CD11b/Mac-1 (clone M1/70), anti-CD3 (clone1452C11), anti-B220 (clone RA3-6B2), or anti-GR1 (clone RB6-8C5; all PharMingen). Cells were incubated at 4°C for 30 min, washed three times, and fixed in PBS/1% paraformaldehyde before analysis on a FACScan® instrument (Becton-Dickinson, Mountain View, CA). FACS® analysis was performed with Lysis II (Becton-Dickinson). Windows for analysis of granulocytes and lymphocytes were set using side scatter and forward scatter.

**Contact Hypersensitivity.** Contact hypersensitivity was elicited in mice by using DNFB. In brief, 6- to 8-wk-old mice were immunized on the shaved abdomen with 50 μl 0.5% DNFB in 4:1 acetone/olive oil at day 0 and day 1. At day 5 these mice were challenged with 10 μl 0.2% DNFB in 4:1 acetone/olive oil on the inner and outer side of one ear. Ear thickness was measured 24 h after reexposition and compared with the untreated ear.

**Thioglycollate-induced Peritonitis.** Aged and sex-matched mice were injected i.p. with 1.5 ml 4% thioglycollate on d 0. At +4, +24, and +72 h mice were injected i.p. with 8 ml of PBS (without Ca²⁺ and Mg²⁺, 2 mM EDTA, 50 μm/ml heparin), their abdomens were massaged and 7 ml of lavage fluid was withdrawn. Peritoneal lavage cells were washed 3× in PBS without Ca²⁺.

1416 Normal Viral Responses but No Tumor Rejection in LFA-1-deficient Mice
and Mg++ and resuspended in 1 ml of same. Total and differential counts were performed after staining with Turk's solution.

**In Vitro Proliferation Assay.** Lymph node (LN) cells from +/+,-/+ and -/- mice were harvested and 10⁶ cells were stimulated hamster anti mouse CD3 mAb (clone 145 2C11; PharMin- gen) (10 μg/ml) in HL-1 media (Hycor Biomedical, Irvine, CA) containing 2% FCS using 96 well round bottom plates. Cells were pulsed overnight with [3H]thymidine after 24, 48, or 72 h. For cross-linking antibody stimulation 96-well flat bottom plates were used and preincubated with rabbit anti–hamster IgG the night before. Cells were pulsed overnight with [3H]thymidine after 48 h. Proliferation was measured by [3H]thymidine incorporation using Matrix 96-Beta-counter.

**Mixed Lymphocyte Reaction (MLR).** MLR’s were performed by mixing spleen cells from C57BL/6j, bm12, BALB/c or B10.BR animals with responder cells from LN cells or enriched T-cells from LNs and spleen of wild-type or mutant hybrid (129sv × C57BL/6j) animals. Stimulator spleen cells were irradiated with 2000R, washed twice and 1 × 10⁶ cells were cocultured with 1 × 10⁶ responder lymph node cells or column enriched T cells (R&D Systems, Inc., Minneapolis, MN). Assays were performed in quadruplicate in 96–well flat-bottom Microtiter plates in HL-1 media (Hycor Biomedical) containing 2% heat inactivated FCS. Cells were pulsed at day 4 with 1 mCi ([3H]thymidine) for 16 h and proliferation measured by [3H]thymidine incorporation using Matrix 96-Beta counter (Camberra Packard).

**Natural Killer Cell Function.** For induction of NK activity in vivo, mice were injected intra-peritoneally with either 100 μg poly(I):poly(C) or saline on days 0 and 1. On day 2 mononuclear spleen cells were isolated by density gradient centrifugation over lympholite M and resuspended at 4 × 10⁶ cells per ml in complete media. Mononuclear cells obtained after in vivo induction of NK activity were coincubated with ³¹Cr-labeled YAC-1 target cells (gift from R. Miller, Ontario Cancer Institute, Toronto, Ontario). Percent specific lysis is given as: % Sp.Lys. = (experimental counts – spontaneous counts)/(total counts – spontaneous counts).

**Homotypic Aggregation of Splenocytes.** Spleen suspension from +/+ and -/- mice were prepared according to standard procedures by straining spleens through mesh. Cells were washed twice and resuspended in DMEM, 5% FCS, Glutamine (200 mM) and b2-ME (10⁻⁶ M). Then 10³-10⁵ cells per well (1 ml) were added to 24–well plates. Cells were incubated for 24 h in the presence of 100 ng/ml PMA. Cell were observed using light microscopy and aggregation was determined as either present or absent.

**Virus.** VSV grown in BHK cells was kindly provided by Dr. Lud Prevec (McMaster University, Hamilton, Ontario, Canada). LCMV (Armstrong isolate) grown in BHK cells was originally obtained from Dr. M.B.A. Oldstone (Sciipps Clinic and Research Foundation, La Jolla, CA) (28).

**Primary Ex Vivo CTL Assay Using Cell Line Targets.** Mice were infected with VSV (2 × 10⁶ pfu i.v.) or with LCMV (2 × 10⁶ pfu i.v.) and spleens were removed after 6 or 8 d, respectively. Spleen cells were coincubated for 5 h with ³¹Cr-labeled MC57 (H-2b) and/or EL-4 (H-2b) target cells, which were infected with VSV or loaded with LCMV-GP peptide (aa33-41, 50 mM, 2 h at 37°C). MC57 cells and EL-4 were infected with VSV for 2 h (15 pfu per cell) before the assay. Specific lysis was calculated as (experimental release – spontaneous release)/(total release – spontaneous release) × 100%.

**Primary Ex Vivo CTL Assay Using Macrophage Targets.** LCMV-specific CTL were derived as above and ex vivo CTL function was determined using targets derived from -/- mutant mice. Target cells were obtained by injecting mice with 1 ml thioglycollate at day -5 and harvesting macrophages by peritoneal lavage at day -1. Macrophages were seeded into flat-bottom 96-well plates and incubated with IMDM 10% FCS containing ³¹Cr sodium chromate (0.2 mCi/ml). Cells were then pulsed with 10⁵ M LCMV-gp peptide. After 2 h, cells were washed twice and spleen cells were added. 5 h later, 70 ml were pipetted off and radioactivity in the supernatant determined in a γ-counter. Since cell numbers and ³¹Cr uptake in individual wells varies, total release of ³¹Cr was determined in each well by lysing cells with 70 μl of HCl (1 M) and counting radioactivity remaining in the well; counts derived from 70 μl supernatant plus remaining counts were taken as 100%.

**Assay for Secondary Responses against VSV.** Mice were immunized i.v. with VSV (2 × 10⁶ p.f.u., Indiana strain). After 6 d spleen cells were restimulated with specific antigen by adding VSV nuclear protein class-I-binding peptide (50 mM) to bulk cultures as previously described (29). After 5 d, in vitro culture were harvested and tested for specific cytotoxicity against VSV-infected EL-4 (H-2b) target cells. Specific lysis was calculated as above.

**Tumor Rejection.** Heterozygous and homozygous mutant mice [129Sv (H-2b) × C57BL/6j (H-2b)] were anesthetized and 2 × 10⁵ MC57 (H-2b) fibrosarcoma-cells (generated from C57BL/6j) were injected into left hind footpads. Footpad swelling was monitored daily or every second day and measured using a spring-loaded caliper. Footpad swelling is given in percent as compared to uninjected footpad. MC57 gp cells were also injected at 2 × 10⁵ cells into the left-hind footpad of mice and injected mice were monitored in the same way, or screened for CTL induction.

**In Vitro Restimulation of Cytotoxic T Cell Activity after Immunization with Tumor.** MC57-GP is a methylcholantren induced fibrosarcoma (originating from C57BL/6 (H-2b) mice) that has been transfected to stably express an LCMV glycoprotein, which contains the immunodominant epitope for CD8+ T cell responses against LCMV infections (described previously in detail [30]). 2 × 10⁵ MC57-GP were injected into the left hind footpads of mice, at day 7 spleens were removed and single cell suspensions restimulated in vitro using irradiated (2,000 rad) LCMV-GP peptide-labeled spleen cells. After 5 d cultures were harvested and tested for generation of LCMV-GP-specific CTL activity against EL-4 target cells, which were labeled with LCMV-GP peptide (aa33-41, 50 mM, 2 h at 37°C). EL-4 cells incubated without peptide were used as controls for specificity. Specific lysis was calculated as (experimental release – spontaneous release)/(total release – spontaneous release) × 100%.

**Results**

**Disruption of CD11a Gene and Generation of Homozygous Mutant Mice.** Successfully targeted ES cells possessed a 9-kb fragment on Southern blotting compared to the 13-kb wild-type fragment using a probe from the 5' flanking region of the CD11a gene (Fig. 1, C and D). All confirmed clones were analyzed with the neo probe to ensure single integration events. Targeted ES cell clones were injected into C57BL/6j blastocysts and male chimeric mice were bred to C57BL/6j mice. Germ line transmission was confirmed by Southern blotting for two of the independently derived ES cell clones. Southern blotting studies from wild-type (+/+), heterozygous (+/-), and homozygous mu-
tant (-/-) mice were performed to document the presence of mutation. The expected 13-kb wild-type and 9-kb targeted fragments were observed using the HindIII/BamHI flanking probe (Fig. 1 E). Additional digestions and the use of neo as a probe confirmed the presence of targeted allele. Heterozygous and homozygous mutant animals were born in expected ratio, survived and grew normally, and were fertile. Animals did not demonstrate any obvious phenotype and remained healthy when maintained under specific pathogen-free conditions.

Splenomegaly and Reduced Lymph Node Size in CD11a −/− Mice. Analysis of 6-wk-old mice (n = 6) did not reveal any gross abnormalities in tissue architecture of major organ systems. However, 6-wk-old mutant mice had two-fold enlargement of spleen, while lymph nodes were approximately one-fourth normal size, reflecting higher and lower numbers of lymphocytes, respectively (data not shown). An interesting exception of these observations was the finding that mesenteric lymph nodes were of normal size and cellularity.
Lymphocyte Subsets Unaltered in CD11a -/- Mice. Despite differences in size and cellularity of spleen and lymph nodes in mutant mice, surface markers indicated that lymphocyte subset ratios were unchanged in these tissues. Analysis of lymphocyte subsets and peripheral blood leukocytes (PBL) confirmed that B220-, CD3-, and CD11b-positive cells were negative for CD11a expression (Figs. 2 and 3). In addition, the cell surface expression of CD18 was reduced to levels expected for its presence only in the MAC-1 heterodimer (Fig. 3). Since thymocyte selection is influenced by thymocyte avidity with stromal cells, which are known to express ICAM-1 (31), the LFA-1 deficiency might be expected to influence thymocyte ontogeny. However, thymocyte cell numbers were normal (data not shown), as were CD4-CD8 profiles (Fig. 4).

Immunoglobulin Levels Are Normal in CD11a -/- Mice. Ig subclass irregularities can reflect general dysfunction of the immune system (32). Moreover, since LFA-1 and ICAM-1 can be upregulated on T and B cells (3), it is conceivable that CD11a might play a role in T:B cell cooperation and, perhaps, in Ig class switching. We found mutant mice housed under pathogen-free conditions to have normal serum Ig levels (IgM, IgG1, IgG2, IgG2a, IgG2b, IgG3, and IgA), suggesting normal B cell and cognate T:B interactions.

CD11a --/- Mouse Have Reduced Thioglycollate-induced Peritonitis. Peritoneal lavage of thioglycollate-induced peritonitis showed a reduction in the total number of infiltrating leukocytes derived from --/- mutant mice. Neutrophils and monocytes exhibit different time courses for extravasation in response to inflammatory stimuli. Accordingly, neutrophil infiltration at 4 h and monocyte infiltration at 24 h was reduced compared to heterozygous controls (Fig. 6).

CD11a --/- CD8+ T Cells Show Normal CTL Effector Function. Since LFA-1 was initially reported as a molecule centrally involved in CTL and NK cell killer function (1, 2, 18, 39, 40), we naturally investigated CTL function in CD11a --/- mutant mice. Mice were injected i.v. with 2 × 10^5 PFU LCMV at day -8 or 2 × 10^6 PFU VSV at day -6. Spleens from infected mice were removed and splenocytes incubated with ^51Cr-labeled target cells infected with VSV or loaded with LCMV peptide (p33). Contrary to expectations from results of previous reports, splenocytes from CD11a --/- mice were found to mount normal in vivo CTL responses to both VSV (Fig. 7, A and B) and LCMV (Fig. 7 D). CTL from VSV-infected mutant mice lysed both ICAM-1-positive (EL-4) (Fig. 7 A) and ICAM-1-negative (MC57) VSV-infected targets (Fig. 7 B) (30).

Ex vivo CTL function was also determined using macrophage target cells derived from thioglycollate-injected CD11a --/- mutant mice. This was intended to assess if compensatory changes in CTL from --/- mice might have masked an obvious defect in CTL responses in vivo. We found no significant difference for CTL-mediated lysis us-
Figure 3. (a) Peripheral blood cells were stained with PE-conjugated anti-CD18 and FITC-conjugated anti-B220 or FITC-conjugated anti-CD3 (top two panels). (b) PBL were stained with PE-conjugated anti-CD11a and FITC-conjugated anti-CD11b. Loss of CD11a expression results in reduction in CD18 surface expression level, which corresponds to expression levels of CD11b on lymphocytes. FACS® data was collected for viable lymphocytes according to SSC and FSC.

Figure 4. Normal T cell subsets in Thymus and Lymph nodes. Leukocytes from +/+, +/-, and −/− CD11a mice. Thymocytes, lymph node cells, and peripheral blood leukocytes were stained with PE-conjugated anti-CD8 and FITC-conjugated anti-CD4. No detectable difference was seen in T cell subsets from these organs. FACS® data was collected for viable lymphocytes according to SSC and FSC.

Secondary Restimulation Against VSV Is Normal in CD11a −/− Mice. Splenocytes from mice immunized with VSV (2 × 10⁶ PFU) were restimulated with VSV nuclear protein class-I–binding peptide in culture for 5 d. Specific cytotoxicity against VSV-infected EL-4 (H-2b) target cells was comparable with wild-type control mice (Fig. 7 C). Specific lysis of non-infected EL-4 cells was below 10% for all effector cells. Spontaneous release was below 20% for both targets.

NK Cytotoxicity Is Markedly Reduced. NK cells from CD11a −/− mice were defective in their ability to kill YAC-1 targets (Fig. 8), and this inhibition was comparable to reduced killing observed after treatment with anti-CD11a mAb (41, 42).

Delayed-type Hypersensitivity Is Absent in CD11a −/− Mice. Anti-LFA-1 mAb treatment during either priming
or rechallenge has been reported to block delayed-type hypersensitivity (DTH) inflammatory responses in mice (16, 17). The DTH responses requires T cell priming in draining lymph nodes and recirculation of T cells to skin. 6–8-wk-old mice were immunized twice with DNFB and rechallenged after 5 d on one ear. After 24 h ear thickness was measured and compared with the untreated ear. Heterozygous littermates showed expected visible swelling of the treated ear while DTH was virtually absent in CD11a−/− mice (Fig. 9).

**CD11a−/− Mice Do Not Prime/Reject Injected Tumor Cells.** We tested the ability of mutant mice to reject a transplant with immunogenic fibrosarcoma tumor cells (MC57, H-2b). In normal mice, injection of these tumor cells into

---

**Figure 5.** Lymphocyte function in mutant mice. (A) Homotypic aggregation of splenocytes from +/+ and −/− mice stimulated with phorbol myristate acetate (PMA 100 ng/ml for 24 h). (B) MLR's were performed by mixing 1 × 10⁶ irradiated spleen cells from C57BL/6, BALB/c, B10.BR, or bml2 mice with 1 × 10⁶ lymph node cells harvested from +/+ (cross-hatched bars) or −/− (open bars) mice. Each bar represents individual mice. (Results are shown for the 5-d time point; similar results were obtained at 3 and 4 d. Similar results were obtained in three independent experiments). (C) Proliferation assay. Lymph node cell suspensions were prepared from +/+ (black bars), +/− (cross-hatched bars), and −/− (open bars) and stimulated. For stimulation by antibody cross-linking, lymph node cells were plated in plates pre-coated with rabbit anti-hamster IgG and hamster anti-murine CD3 MAb (10 µg/ml). (D) Proliferative responses to soluble anti-CD3. 10⁶ lymph node cells were plated into each well and purified hamster anti-murine CD3 added (10 µg/ml). Between 24 and 72 h, proliferating cells were pulsed with [3H]thy-midine and cultured overnight. Data represent averages of quadruplicates. (Closed triangles +/+; closed squares +/−; open triangles −/−.)

---

**Figure 6.** Leucocyte migration in response to intraperitoneal injection of thioglycollate. Total leucocyte (A), polymorphonuclear leucocyte (B) and monocyte (C) numbers were assessed at the indicated time points after i.p. injection of 1.5 ml of 4% thioglycollate in +/+ and −/− mutant mice. Data shown as mean +/- SEM for groups of five age- and sex-matched animals per time point. Solid circles are +/+ mice; open circles are −/− mutant mice.
footpads induces lymphocytic infiltration of footpads and a visible swelling reaction by 6–9 d, followed by tumor clearance and normalization of footpad thickness within 14 d. CD11a mutant mice showed no swelling at 6–9 d, and developed massive tumor burdens by day 14 (Fig. 10). Histologic analysis of LFA-1 expressing (Fig. 4, B and C) and mutant mouse footpads confirmed the presence of malignant cells and the absence of leukocytes (Fig. 10, D and E). We then immunized mice into footpads with the fibrosarcoma cell line MC57-gp (the same MC57 cell line as above transfected to express the major immunogenic epitope of the LCMV glycoprotein [30]) to induce CD8+ CTL responses against LCMV in H-2b mice (43). 7 d after injection of live MC57-gp into footpads, LCMV-gp-specific CD8+ CTL became detectable in spleens of CD11a+/− mice but not in CD11a−/− mice (Fig. 10F). Accordingly, CD11a+/− mice, but not CD11a−/− mice, cleared the MC57-gp tumor cells (data not shown).

Discussion

The role of adhesion molecules during the cellular immune response is multifaceted and involves functions asso-
associated with recirculation through the lymphatic network, interaction with and migration through endothelial lining of blood vessels, cellular adhesion events important during antigen specific activation, and, finally, cell contact during T cell effector functions (reviewed by Springer et al. [9]). In vitro and in vivo findings suggest that LFA-1 is important in lymphocyte migration across the HEV into peripheral LN and Peyer’s patches (22). Thus it would be expected that immune responses to peripheral antigens, where priming of T cell responses occurs in the draining lymph nodes, would be defective in LFA-1-deficient mice. We used intravenous infection to assess CTL responses in mutant mice. Because i.v. infection results in a viremia and dissemination of virions lymphocytes are likely to be primed in the spleen, circumventing the need for efficient lymphocyte recirculation through lymph nodes and migration across endothelial barriers.

Nevertheless, in contrast to reports that LFA-1 is crucial
for lymphocyte proliferation against virus-infected cells and CTL effector function (1, 18, 19), ex vivo assays from LCMV- and VSV-infected CD11a-/- mutant mice revealed that LFA-1 deficient CTL had no defect in killing cell line-derived targets. These assays also suggested that antigen-specific CTL had undergone sufficient proliferation in vivo for normal killing responses ex vivo. The implication of these observations is that LFA-1-deficient T cells are capable of undergoing activation and proliferation with no discernable defect compared to normal mice. Reports that lymphocyte proliferation and CTL function is defective after anti-LFA-1 antibody treatment might be a characteristic of the in vitro nature of the assay, or might reflect non-specific effects of antibody treatment, such as capping of other crucial surface molecules or even killing of effector cells. On the other hand, T cells developing in LFA-1-deficient mice may have compensatory alterations in the expression of other molecules that may serve to mask the LFA-1 defect. Ex vivo CTL function using +/- or -/- CTL against targets derived from CD11a -/- mice suggested that CD11a -/- effectors were no better at killing -/- targets than were effector cells that had developed in mice with normal levels of LFA-1. If T cell development in CD11a -/- mice had managed to compensate for the LFA-1 defect, as evidenced by normal response in vivo to virus, it was not evident in a differential ability to kill -/- targets in vitro. If anything, +/- effectors appeared to be slightly better at killing -/- targets in this sensitive assay, which may reflect a slightly outperformance (proliferation and or killer function) of T cells from LFA-1-expressing mice. It should be mentioned that mutant mice also have about twofold greater number of splenocytes than heterozygous mice, thus any minor defect in CTL responses to virus in mutants may be overcome by the sheer excess of T cells present.

Peritoneal lavage after thioglycollate treatment indicated that LFA-1 is not crucial but nevertheless important in extravasation of polymorphonuclear leukocytes and monocytes into the peritoneum in response to inflammatory stimulus. Observed decreases in infiltrate reflected an absolute reduction in cell numbers rather than a shift in the kinetics of the inflammatory response. This finding suggests a significant role for LFA-1 in neutrophil and monocyte responses to local infection.

DTH responses against DNFB were virtually absent in LFA-1-deficient mice. Moreover, immunization in the base of the tail with KLH or OVA in CFA or incomplete FA had little affect on the size of inguinal or paraortic LNs, whereas similar treatment on heterozygous mice resulted in marked lymphadenopathy (data not shown). Both of these situations could be explained by a recirculation defect, but do not rule out a defect in priming. The lack of tumor rejection after inoculation of MSV fibrosarcoma cells into footpads and the failure of LCMVgp-transfected MSV cells to prime antigen-specific responses are also consistent with a recirculation defect in CD11a -/- mice.

Although this is the first report that LFA-1 is crucial for priming immune responses against non-virus-induced syngeneic tumors, these results again do not determine if a defect in priming in draining peripheral LN accompanies a lymphocyte recirculation defect. However, our studies with LCMV and VSV infections suggests that priming is efficient in the absence of LFA-1, at least, as it appears, in the context of virus infestations in the spleen. Differential priming requirements could reflect the involvement of different types of APC in the peripheral lymph nodes versus the spleen (24). The importance of the strength of the activation signal in LFA-1-deficient cells is exemplified by our finding that proliferative responses of CD11a-/- lymphocytes was absent after treatment with soluble CD3 but relatively normal after treatment with cross-linked anti-CD3 mAb. Our in vitro findings that proliferation of CD11a -/- lymphocytes is significantly reduced contrasts with in vivo responses of CD11a -/- mice to systemic virus infections. Taken together, our results suggest a differential requirement for LFA-1 for lymphocyte activation and proliferation depending, perhaps, on the type of APC involved in presenting antigen to T cells, or, on the microenvironment in which antigen presentation occurs.

Supported by grants from the Medical Research Council of Canada, the National Cancer Institute of Canada, and the National Science and Engineering Research Council of Canada. R. Schmits was supported by the Dr. Mildred-Scheel Stiftung, Germany; T.M. Kündig was supported by the Swiss National Science Foundation; T.W. Mak was supported by the Medical Research Council of Canada; D.D. Hickstein was supported by the National Institutes of Health and the Veterans Affairs Career Development and Merit Review program.

Address correspondence to Dr. T.W. Mak, Ontario Cancer Institute, Princess Margaret Hospital, 610 University Ave., Toronto, Ontario, Canada M5G 2M9.

Received for publication 13 November 1995 and in revised form 5 February 1996.

References

1. Davignon, D., E. Martz, T. Reynolds, K. Kurzinger, and T.A. Springer. 1981. Monoclonal antibody to a novel lymphocyte function-associated antigen (LFA-1): mechanism of blockade of T lymphocyte-mediated killing and effects on
other T and B lymphocyte functions. *J. Immunol.* 127:590–595.

2. Sanchez Madrid, F., A.M. Krensky, C.F. Ware, E. Robbins, J.L. Strominger, S.J. Burakoff, and T.A. Springer. 1982. Three distinct antigens associated with human T-lymphocyte-mediated cytosis: LFA-1, LFA-2, and LFA-3. *Proc. Natl. Acad. Sci. USA.* 79:7489–7493.

3. Springer, T.A. 1990. Adhesion receptors of the immune system. *Nature (London).* 346:425–434.

4. Springer, T.A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell.* 76:301–314.

5. Starling, G.C., A.D. Mclellan, W. Egner, R.V. Sorg, J. Fawcett, D.L. Simmons, and D.N. Hart. 1995. Intercellular-adhesion molecule-3 is the predominant costimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells. *Eur. J. Immunol.* 25:2528–2532.

6. Sligh, J.E., Jr., C.M. Ballantyne, S.S. Rich, H.K. Hawkins, C.W. Smith, A. Bradley, and A.L. Beaudet. 1993. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. *Proc. Natl. Acad. Sci. USA.* 90:8529–8533.

7. Danilenko, D.M., P.V. Rossitto, M. Vandervieren, H. Jacobs, T.C. Waldrop et al. 1985. The severe and moderate clinical features of C3bi receptor deficiency. *J. Exp. Med.* 161:1473–1479.

8. Springer, T.A., M.L. Dustin, T.K. Kishimoto, and S.D. Mar- ton. 1987. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. *Annu. Rev. Immunol.* 5:223–252.

9. Anderson, D.C., F.C. Schmalsteig, M.J. Finegold, B.J. Hughes, R. Rothlein, I.J. Miller, S. Kohl, M.F. Tosi, R.L. Jacobs, T.C. Waldrop et al. 1985. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. *J. Infect. Dis.* 152:668–689.

10. Arnaut, M.A., H. Spits, C. Terhorst, J. Pitt, and R.F. Todd. 1984. Deficiency of a leukocyte surface glycoprotein (LFA-1) in two patients with Mo1 deficiency. Effects of cell activation on Mo1/LFA-1 surface expression in normal and deficient leukocytes. *J. Clin. Invest.* 74:1291–1300.

11. Beatty, P.G., H.D. Ochs, J.M. Harlan, T.H. Price, H. Rosen, R.F. Taylor, J.A. Hansen, and S.J. Klevanoff. 1984. Absence of monoclonal-antibody-defined protein complex in boy with abnormal leucocyte function. *Lancet.* 1:535–537.

12. Buescher, E.S., T. Gaither, J. Nath, and J.I. Gallin. 1985. Abnormal adherence-related functions of neutrophils, monocytes, and Epstein-Barr virus-transformed B cells in a patient with C3bi receptor deficiency. *Blood.* 65:1382–1390.

13. Butcher, E.C. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. *Cell.* 67:1033–1036.

14. Krensky, A.M., F. Sanchez Madrid, E. Robbins, J.A. Nagy, T.A. Springer, and S.J. Burakoff. 1983. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. *J. Immunol.* 131:611–616.

15. Scheynius, A., R.L. Camp, and E. Pure. 1993. Reduced contact sensitivity reactions in mice treated with monoclonal anti-bodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. *J. Immunol.* 150:655–663.

16. Anderson, E.C., J.P. Christensen, A. Scheinuis, O. Marker, and A.R. Thomsen. 1995. Lymphocytic choriomeningitis virus-infection is associated with long-standing perturbation of LFA-1 expression on CD8(+) T-cells. *Scand. J. Immunol.* 42:110–118.

17. Davignon, D., E. Martz, T. Reynolds, K. Kurzinger, and T.A. Springer. 1981. Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2,3. *Proc. Natl. Acad. Sci. USA.* 78:4535–4539.

18. Springer, T.A., D. Davignon, M.K. Ho, K. Kurzinger, E. Martz, and F. Sanchez Madrid. 1982. LFA-1 and Lyt-2,3, molecules associated with T lymphocyte-mediated killing; and Mac-1, an LFA-1 homologue associated with complement receptor function. *Immunol. Rev.* 103:171–195.

19. T.A. Springer, T. 1990. Adhesion receptors of the immune system. *Nature (London).* 346:425–434.

20. Springer, T.A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell.* 76:301–314.

21. Starling, G.C., A.D. Mclellan, W. Egner, R.V. Sorg, J. Fawcett, D.L. Simmons, and D.N. Hart. 1995. Intercellular-adhesion molecule-3 is the predominant costimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells. *Eur. J. Immunol.* 25:2528–2532.

22. Sligh, J.E., Jr., C.M. Ballantyne, S.S. Rich, H.K. Hawkins, C.W. Smith, A. Bradley, and A.L. Beaudet. 1993. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. *Proc. Natl. Acad. Sci. USA.* 90:8529–8533.

23. Danilenko, D.M., P.V. Rossitto, M. Vandervieren, H. Jacobs, T.C. Waldrop et al. 1985. The severe and moderate clinical features of C3bi receptor deficiency. *J. Exp. Med.* 161:1473–1479.

24. Springer, T.A., M.L. Dustin, T.K. Kishimoto, and S.D. Martin. 1987. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. *Annu. Rev. Immunol.* 5:223–252.

25. Anderson, D.C., F.C. Schmalsteig, M.J. Finegold, B.J. Hughes, R. Rothlein, I.J. Miller, S. Kohl, M.F. Tosi, R.L. Jacobs, T.C. Waldrop et al. 1985. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. *J. Infect. Dis.* 152:668–689.

26. Arnaut, M.A., H. Spits, C. Terhorst, J. Pitt, and R.F. Todd. 1984. Deficiency of a leukocyte surface glycoprotein (LFA-1) in two patients with Mo1 deficiency. Effects of cell activation on Mo1/LFA-1 surface expression in normal and deficient leukocytes. *J. Clin. Invest.* 74:1291–1300.

27. Beatty, P.G., H.D. Ochs, J.M. Harlan, T.H. Price, H. Rosen, R.F. Taylor, J.A. Hansen, and S.J. Klevanoff. 1984. Absence of monoclonal-antibody-defined protein complex in boy with abnormal leucocyte function. *Lancet.* 1:535–537.

28. Buescher, E.S., T. Gaither, J. Nath, and J.I. Gallin. 1985. Abnormal adherence-related functions of neutrophils, monocytes, and Epstein-Barr virus-transformed B cells in a patient with C3bi receptor deficiency. *Blood.* 65:1382–1390.

29. Butcher, E.C. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. *Cell.* 67:1033–1036.

30. Krensky, A.M., F. Sanchez Madrid, E. Robbins, J.A. Nagy, T.A. Springer, and S.J. Burakoff. 1983. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. *J. Immunol.* 131:611–616.
H. Hengartner, and R.M. Zinkernagel. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science (Wash. DC). 268:1343–1347.

31. Lepesant, H., H. Leggio, M. Pierres, and P. Naquet. 1990. Mouse thymic epithelial cell lines interact with and select a CD3lowCD4+CD8+ thymocyte subset through an LFA-1-dependent adhesion—de-adhesion mechanism. Int. Immunol. 2:1021–1032.

32. Shackelford, P.G., D.M. Granoff, S.H. Polmar, M.G. Scott, M.C. Goskowicz, J.V. Madassery, and M.H. Nahm. 1990. Subnormal serum concentrations of IgG2 in children with frequent infections associated with varied patterns of immunologic dysfunction. J. Pediatr. 116:529–538.

33. Rothenfus, R., and T.A. Springer. 1986. The requirement for lymphocyte function-associated antigen 1 in homotypic leukocyte adhesion stimulated by phorbol ester. J. Exp. Med. 163:1132–1149.

34. Patrocco, M., P.G. Beatty, J.W. Fabre, and C.G. Gahmberg. 1985. Identification of a cell surface protein complex mediating phorbol ester-induced adhesion (binding) among human mononuclear leukocytes. Scand. J. Immunol. 22:171–182.

35. Springer, T.A., R. Rothenfus, D.C. Anderson, S.J. Burakoff, and A.M. Krensky. 1985. The function of LFA-1 in cell-mediated killing and adhesion: studies on heritable LFA-1, Mac-1 deficiency and on lymphoid cell self-aggregation. Adv. Exp. Med. Biol. 184:311–322.

36. Mentzer, S.J., S.H. Herrmann, M.A. Crimmins, S.J. Burakoff, and D.V. Fallar. 1988. The role of CD18 in phorbol ester-induced human monocyte-mediated cytotoxicity. Cell. Immunol. 115:66–77.

37. Carreras, A.C., M. Rincon, F. Sanchez Madrid, M. Lopez Botet, and M.O. de Landazuri. 1988. Triggering of co-mitogenic signals in T cell proliferation by anti-LFA-1 (CD18, CD11a), LFA-3, and CD7 monoclonal antibodies. J. Immunol. 141:1919–1924.

38. van Noesel, C., F. Miedema, M. Brouwer, M.A. de Rie, L.A. Aarden, and R.A. van Lier. 1988. Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature (Lond.). 333:850–852.

39. Hildreth, J.E., F.M. Gotch, P.D. Hildreth, and A.J. Michael. 1983. A human lymphocyte-associated antigen involved in cell-mediated lympholysis. Eur. J. Immunol. 13:202–208.

40. Pierres, M., C. Goridis, and P. Golstein. 1982. Inhibition of murine T cell-mediated cytosis and T cell proliferation by a rat monoclonal antibody immunoprecipitating two lymphoid cell surface polypeptides of 94 000 and 180 000 molecular weight. Eur. J. Immunol. 12:60–69.

41. Krensky, A.M., F. Sanchez-Madrid, E. Robbins, J.A. Nagy, T.A. Springer, and S.J. Burakoff. 1983. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J. Immunol. 131:611–616.

42. Kohl, S., T.A. Springer, F.C. Schmalstieg, L.S. Loo, and D.C. Anderson. 1984. Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J. Immunol. 133:2972–2978.

43. Pircher, H., D. Moskophidis, U. Rohrer, K. Burki, H. Hengartner, and R.M. Zinkernagel. 1990. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (Lond.). 346:629–633.

44. Champe, M., B.W. McIntyre, and P.W. Berman. 1995. Monoclonal-antibodies that block the activity of leukocyte function-associated antigen-1 recognize 3 discrete epitopes in the inserted domain of CD11a. J. Biol. Chem. 270:1388–1394.

1426 Normal Viral Responses but No Tumor Rejection in LFA-1-deficient Mice